CustomCustomCustomCustomCustomCustom
13 01, 2020

New evidence for the clinical utility of platelet microRNA biomarkers for monitoring treatment response

2023-03-10T10:54:03+01:00January 13th, 2020|biomarker, biomarkers, clopidogrel, diabetes, microRNAs, Personalized medicine, platelet activation, platelet-associated miRNAs, thrombomiR, type 2 diabetes mellitus|Comments Off on New evidence for the clinical utility of platelet microRNA biomarkers for monitoring treatment response

We want to draw your attention to the latest publication of the King's College London, in Cardiovascular Diabetology. The research team provides new evidence for the clinical utility of platelet microRNA biomarkers for monitoring treatment response in type-2 diabetics with cardiovascular disease. "Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus: a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levels." Parker WAE, Schulte C, Bawari T, et al. Cardiovasc Diabetol. 2020 Jan 7;19(1):3. doi: 10.1186/s12933-019-0981-3. click here to read the story

Read More
1 01, 2020

meet TAmiRNA 2020

2023-03-10T10:54:36+01:00January 1st, 2020|biomarker, biomarkers, microRNAs, Personalized medicine|Comments Off on meet TAmiRNA 2020

2020 TAmiRNA showcases at several conferences - take advantage, meet the TAmiRNA experts and discuss our latest developments and your needs! 2nd Longevity Therapeutics conference, 28-30 January 2020, San Francisco, California, USA SOT 59th Annual Meeting and ToxExpo, 15-19 March 2020, Anaheim, California, USA - cancelled Osteologie 2020, 5-6 September 2020, virtual meeting 47th annual meeting of the European Calcified Tissue Society, 22-24 October 2020, Marseille, France, virtual meeting

Read More
18 11, 2019

MicroRNA levels in bone and blood change during bisphosphonate and teriparatide therapy in an animal model of postmenopausal osteoporosis.

2023-03-10T10:55:04+01:00November 18th, 2019|biomarker, biomarkers, bone diseases, bone fracture risk assessment, microRNAs, osteomiR, osteoporosis, Personalized medicine|Comments Off on MicroRNA levels in bone and blood change during bisphosphonate and teriparatide therapy in an animal model of postmenopausal osteoporosis.

We want to draw your attention to the latest publication of the Ludwig Boltzmann Institute for Experimental and Clinical Traumatology in AUVA Research Center, in cooperation with TAmiRNA GmbH, in Bone. "MicroRNA levels in bone and blood change during bisphosphonate and teriparatide therapy in an animal model of postmenopausal osteoporosis." Kocijan R, Weigl M, Skalicky S, et al. Bone 2019 Volume 131, February 2020, 115104. https://doi.org/10.1016/j.bone.2019.115104 Take the chance and download the paper

Read More
7 11, 2019

Serum microRNA as novel biomarkers for osteoporotic vertebral fractures.

2023-03-10T10:55:55+01:00November 7th, 2019|biomarker, biomarkers, bone diseases, bone fracture risk assessment, microRNAs, osteomiR, osteoporosis, Personalized medicine|2 Comments

We want to draw your attention to the latest publication of the Department of Oncology and Metabolism, University of Sheffield, United Kingdom, in cooperation with TAmiRNA GmbH, in Bone. "Serum microRNA as novel biomarkers for osteoporotic vertebral fractures." Zarecki P, Hackl M, Grillari J, et al. Bone 2019 Oct 24:115105. doi: 10.1016/j.bone.2019.115105. Specific circulating miRNAs reflect the presence of osteoporotic vertebral fractures in postmenopausal women. They are unlikely to reflect low BMD, and more likely changes in bone quality or fracture healing. Take the chance and download this paper by clicking here

Read More
5 11, 2019

Combining laser microdissection and microRNA expression profiling to unmask microRNA signatures in complex tissues

2023-03-10T10:56:26+01:00November 5th, 2019|biomarker, biomarkers, drug development, drug discovery, LMD, microRNAs, Personalized medicine, safety, Vivomicx|Comments Off on Combining laser microdissection and microRNA expression profiling to unmask microRNA signatures in complex tissues

We want to draw your attention to the latest publication with our partner Vivomicx. Together we have developed a combination of laser microdissection (LMD) and high quality qPCR, which enables the quantitative analysis of cell-type specific RNA expression in complex tissues. Using this protocol TAmiRNA & Vivomicx have been able to demonstrate: the profound difference of RNA expression between whole tumor and subsets of cells within the tumor and the large heterogeneity in RNA expression between colorectal* tumor compartments such as tumor, stroma and tumor endothelial cells. * Note: the technology can be utilized for almost any tissue sample. Our new approch allows to: Discover differential expression patterns between “healthy” and “diseased” tissues on the cellular level; [...]

Read More
24 10, 2019

meet TAmiRNA 2019

2023-03-10T11:04:50+01:00October 24th, 2019|biomarker, biomarkers, microRNAs, Personalized medicine|Comments Off on meet TAmiRNA 2019

2019 TAmiRNA showcases at several conferences 63rd Annual Meeting of the Society of Thrombosis and Haemostasis Research, 27 February-2 March 2019, Berlin, Germany 9th international Gene Quantification Event, 18-22 March, Freising-Weihenstephan, Germany ECTS (European Calcified Tissue Society) 2019, 11-14 May 2019, Budapest, Hungary The 9th International Conference on Children’s Bone Health, 22-25 June 2019, Salzburg, Austria British Orthopaedic Society, 4-6 September 2019, Cardiff, UK ASBMR 2019 Annual Meeting, 20-23 September 2019, Orlando, Florida Safety Pharmacology Society Annual Meeting, 23-26 September 2019, Barcelona, Spain Knochen, Muskeln und Gelenke - Update 2019 "Neues aus der Forschung und Klinik", 8-9 November 2019, Berlin, Germany BIO-Europe, 11-13 November 2019, Hamburg, Germany RNA Targeting conference, 26-27 November 2019, Frankfurt. Germany

Read More
18 09, 2019

TAmiRNA GmbH is part of the EU-funded Innovative Training Network FIDELIO

2023-03-10T11:00:49+01:00September 18th, 2019|biomarkers, bone diseases, diabetes, microRNAs, Personalized medicine|Comments Off on TAmiRNA GmbH is part of the EU-funded Innovative Training Network FIDELIO

Diabetes mellitus is a widespread metabolic disease, with negative/adverse effects on many organ systems. Diabetes also significantly affects bone health. An increased risk of bone fractures and impaired fracture healing has been observed in patients, but the mechanisms are not fully understood. In order to investigate the links between diabetes and the bone system, the EU project "FIDELIO" will run for four years starting October 2019. This European Training Network, coordinated by scientists from the Faculty of Medicine of the Technical University of Dresden, is funded by the EU Marie Skłodowska-Curie Actions program with a total of 3.8 million €. FIDELIO aims to train the next generation of scientists in order to tackle the challenges of diabetic [...]

Read More
26 06, 2019

University Medical Center Groningen (UMCG) , TAmiRNA GmbH & Vivomicx BV announce their collaboration to unmask the molecular signature of sepsis induced multi organ failure.

2023-03-10T10:59:37+01:00June 26th, 2019|biomarkers, LMD, microRNAs, safety, Vivomicx|Comments Off on University Medical Center Groningen (UMCG) , TAmiRNA GmbH & Vivomicx BV announce their collaboration to unmask the molecular signature of sepsis induced multi organ failure.

UMCG, TAmiRNA, and Vivomicx today announced their collaboration to unmask the molecular signature of sepsis induced multi organ failure and shed light on diagnosis and therapeutic options. Sepsis is the body’s response to infection. Sepsis kills and disables millions of patients worldwide. The role of the microvasculature in all organs has been identified as central, yet understudied in the pathophysiology leading to Multi Organ Failure (MOF) in critically ill patients with sepsis. This translational project combines cutting edge molecular research at the level of kinome, gene expression, and microRNome in samples of patients who suffered from sepsis and of animal models of this disease. In both human and mouse lungs and kidneys we will enrich the samples [...]

Read More
30 04, 2019

TAmiRNA is part of the international IMI2 project “Translational Safety Biomarker Pipeline”

2023-03-10T11:01:16+01:00April 30th, 2019|biomarkers, drug development, drug discovery, exosomes, liquid biopsies, microRNAs, Personalized medicine, safety|Comments Off on TAmiRNA is part of the international IMI2 project “Translational Safety Biomarker Pipeline”

Early and reliable detection and monitoring of adverse events is essential for improving of patient safety, reducing late attrition of drug candidates, and enhancing understanding of toxic mechanisms. The Translational Safety Biomarker Pipeline (TransBioLine) project will focus on development of biomarkers of injury for liver, kidney, pancreas, vasculature, central nervous system (CNS) and the development of non-invasive microRNA biomarkers using liquid biopsies. The project is coordinated by the University of Zurich with Pfizer as industry lead, and involves 27 partners (pharmaceutical companies, small and medium-sized enterprises, and academic institutions) from ten European countries and the United States of America. With a total budget of € 28 million, the EU and the pharmaceutical companies involved are financing the [...]

Read More
30 04, 2019

TAmiRNA and advanceCOR receive Eurostars project “thrombomiR”

2023-03-10T11:01:46+01:00April 30th, 2019|biomarkers, drug development, drug discovery, microRNAs, Personalized medicine, safety, thrombomiR|Comments Off on TAmiRNA and advanceCOR receive Eurostars project “thrombomiR”

TAmiRNA and advanceCOR, a drug developing biotechnology company which focuses on personalized medicine in cardiovascular diseases, receive Eurostars project entitled: ”A novel microRNA-based platelet function biomarker for personalized anti-thrombotic treatment”.  The aim of the Eurostars project is to validate the use of the thrombomiR™ kit for management of anti-thrombotic therapies. The thrombomiR™ kit is a minimally invasive blood test that can determine changes in platelets reactivity (for example due to a therapy), based on the quantitative analysis of microRNAs, Specifically, the thrombomiR™ kit allows the targeted detection and quantitation of platelet-specific microRNAs in blood plasma. The concentration of these microRNAs increases in the course of activation of platelets and decreases as a result of therapeutic inactivation. Thus, [...]

Read More
© Copyright TAmiRNA 2019 - 
 
Go to Top